BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease
Detection of Remaining Cancer Cells After Complete Remission is the Strongest Prognostic Factor for Relapse in Patients With Acute Lymphoblastic Leukemia
Accelerated Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia
PR Newswire
THOUSAND OAKS, Calif., March 29, 2018